CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 MEDICAL DELIVERY SYSTEM Cross-Reference to Related Applications This application claims the benefit of, and priority to, U.S. Provisional Application Serial No. 62/326,977, filed April 25, 2016 and to U.S. Provisional Application Serial No. 62/474,096, filed March 21, 2017, the contents of each of which are hereby incorporated by reference herein in their entireties. Field of the Invention The present invention generally relates to delivery devices for delivering substances, such as medicaments, and, more particularly, to a delivery system including a delivery assembly configured to allow delivery of a single dose of a therapeutic agent from a blow-fill-seal (BFS) vial to a patient. Background Every year, millions of people become infected and die from a variety of diseases, some of which are vaccine-preventable. Although vaccination has led to a dramatic decline in the number of cases of several infectious diseases, some of these diseases remain quite common. In many instances, large populations of the world, particularly in developing countries, suffer from the spread of vaccine-preventable diseases due to ineffective immunization programs, either because of poor implementation, lack of affordable vaccines, or inadequate devices for administering vaccines, or combinations thereof. Some implementations of immunization programs generally include administration of vaccines via a typical reusable syringe. However, in many situations, particularly in developing countries, the administration of vaccines occur outside of a hospital and may be provided by a non-professional, such that injections are given to patients without carefully controlling access to syringes. The use of reusable syringes under those circumstances increases the risk of infection and spread of blood-borne diseases, particularly when syringes, which have been previously used and are no longer sterile, are used to administer subsequent injections. For example, the World Health Organization (WHO) estimates that blood-borne diseases, such as Hepatitis and human 1 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 immunodeficiency virus (HIV), are being transmitted due to reuse of such syringes, resulting the death of more than one million people each year. Summary The present invention provides a delivery system that overcomes the drawbacks of current delivery devices and methods. In particular, the delivery system of the present invention includes a delivery assembly configured to be coupled to a source containing a fluid agent (e.g., vaccine, drug, medicament, etc.) and further facilitate delivery of a single dose of the fluid agent from the source to a patient. The delivery assembly is configured to be filled on-site and in the field with a single dose of a fluid agent, while remaining sterile and preventing the potential for contamination during the filling process. The delivery assembly is further capable of delivering the fluid agent in a controlled manner and without requiring specialized skill in administering delivery of such agent. In particular, the delivery assembly of the present invention is configured to be coupled to a source containing the fluid agent, including, but not limited to, a blow- fill-seal (BFS) vial. The delivery assembly includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another. The components of the delivery assembly include a hub member configured to be securely coupled to the BFS vial, a one-way valve member positioned within the hub member and configured to limit fluid flow to an antegrade direction, and an insert positioned within the hub member and configured to receive and retain an administration member for receiving the fluid agent from the BFS vial and administering the fluid agent into a patient. The administration member may include, for example, a needle (for subcutaneous, intramuscular, intradermal, or intravenous injection of the fluid agent) or a nozzle (e.g., spray nozzle to facilitate dispersion of the fluid agent into a spray or a droplet nozzle for formation of droplets). In one aspect, the hub member may include a proximal end defining an inlet port and a distal end defining an outlet port and a channel extending entirely from the proximal end to the distal end, thereby providing a fluid pathway between inlet and outlet ports. The inlet port includes a specialty, non-standard (non-Luer-type connection) connection fitting configured to be coupled with a corresponding specialty, non-standard connection fitting of the BFS vial. For example, the inlet port may include recesses, depressions, or complete apertures of a particular 2 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 shape or geometry which are shaped and/or sized to receive correspondingly shaped and/or sized protrusions, projections, or the like on the BFS vial. In one embodiment, the inlet port may include two opposing apertures on either side of the hub member. The BFS vial may generally include a flexible body having an interior volume sufficient to contain at least one dose of the fluid agent within. The BFS vial further includes a neck extending from the body and terminating at a distal end defining an outlet for dispensing the fluid agent upon squeezing of the vial body. The vial may include two protrusions defined on opposing sides of the neck adjacent to the distal end and having a general shape corresponding to the apertures on the hub member. Upon a user inserting the distal end of the vial into the inlet port of the hub member, the protrusions may be shaped so as to slide into engagement with the corresponding apertures but further shaped to prevent withdrawal of the BFS vial from the hub member, thereby effectively locking themselves within the apertures and effectively locking the BFS vial into engagement with the delivery assembly. By securing the vial to the hub member, a user need only apply force to (i.e. squeeze) the vial body to cause the fluid agent to flow from the vial, through the delivery assembly, and to the patient. The specialty, non-standard connection fitting between the hub member and the BFS vial allows for only approved sources (e.g., single-dose BFS vials) with a corresponding agent to be used with the delivery assembly of the present disclosure, thereby adding one more layer of security. For example, the method of delivery is generally dependent on the type of fluid agent to be delivered. For example, some medicaments are best delivered intravenously while some vaccines are best delivered intradermally, and yet still, some fluid agents are administered via droplets or spray. Accordingly, the deliver assembly may configured for delivery of a specific fluid agent and thus the connection fitting on the hub member may be designed so as to only accept and engage a corresponding connection fitting of a BFS vial containing that specific fluid agent. Accordingly, the specialty connection fitting design of the present disclosure ensures that only the matching BFS vial (which contains the correct fluid agent for that specific delivery assembly) is able to be connected to the delivery assembly, thereby ensuring safety and reducing risk. As previously described, the delivery assembly further includes a one-way valve and an insert within the hub member. The one-way valve is positioned within the within the channel of the hub member and configured to limit fluid flow to an antegrade direction from the inlet port 3 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 towards the outlet port, thereby ensuring that fluid flows in a single direction when the vial body is squeezed for delivery. The insert is positioned within the channel adjacent to the outlet of the hub member. The insert includes a proximal end and an opposing distal end and a channel extending entirely through the insert from the proximal end to the distal end. The channel of the insert is in coaxial alignment with the channel of the hub member, such that the fluid pathway extends entirely from the inlet port of the hub member, through the one-way valve, and through the channel of the insert towards the distal end of the insert. The administration member (e.g., needle, nozzle, etc.) is further received and retained within the channel of the insert, such that, upon delivery of the fluid agent from the BFS vial and through the fluid pathway of the delivery assembly, the fluid agent will flow out of the administration member, thereby allowing for delivery of the fluid agent to the patient. The delivery assembly further includes a safety cover for covering the administration member to prevent contamination and further reduce the risk of needlestick injuries, and thus reduce the potential for spreading blood-borne diseases. The delivery assembly may generally be packaged and delivered in a fully assembled state, including the safety cover provided over the needle or nozzle. Accordingly, a user does not have to deal with an exposed needle or nozzle when first attaching a BFS vial to the delivery assembly. Rather, the user need only remove the safety cover once the BFS vial has been securely attached to the delivery assembly to thereby expose the needle or nozzle for fluid agent delivery. The user may then replace the cover once delivery is complete. The modular construction of the delivery assembly allows for rapid manufacturing reconfigurations of one or more components with minimal costs to create new delivery assembly configurations that meet specific needs (i.e., different modes of delivery depending on agent to be delivered, such as subcutaneous, intramuscular, intradermal, intravenous injection, spray, or droplet delivery). For example, the hub member and the one-way valve may remain the same construction (dimensions and material), while the insert may be changed to account for different needle sizes and/or nozzle types, depending on the type of delivery and/or type of fluid agent to be delivered. The delivery assembly itself is not prefilled. As such, the delivery assembly of the present invention does not require the maintenance of a certain temperature (e.g., 2 to 8 degrees Celsius) during shipment or storage, thus cutting down on the overall costs. Rather than 4 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 maintaining the delivery assembly at a constant temperature, as is the case with current devices, only the source containing the fluid agent (e.g., single dose supply provided in a BFS vial) need by maintained at a constant temperature. Accordingly, a plurality of empty delivery assemblies may be shipped and stored, at a reduced cost, and then filled directly on-site and on an as-needed basis, such that only the single-dose BFS vials need be stored and maintained. Additionally, because the delivery device is not prefilled, it may be sterilized at any point prior to being filled with the fluid agent, which further improves the bulk shipping and storage of such devices. The delivery assembly is configured to allow delivery of the agent to the patient in a relatively simple manner, without requiring specialized training for administering the agent. In particular, the delivery assembly is designed such that a person administering the fluid agent (e.g., administrator), which could also include self-administration, need only position the device upon the administration site (e.g., shoulder, arm, chest, nose, ear, eye, etc.), and then fully compress the BFS vial body containing the dose of fluid agent, thereby delivering the correct predefined dosage to the patient. The delivery assembly is further configured such that, in the event that a needle is required (i.e., because the delivery method is an injection), needle penetration is limited to the correct length and orientation within the administration site. For example, in some embodiments, the needle is positioned substantially perpendicular relative to a plane along which the distal end of the insert lies, such that the needle is configured to be inserted into a patient's skin at a substantially perpendicular angle and the distal end of the insert is configured to contact the patient's skin indicating adequate depth of penetrating for injection of the fluid agent. Accordingly, the delivery assembly of the present invention does not require a trained, skilled healthcare profession for administration of vaccines or drugs. As such, the delivery assembly may be particularly useful in situations in which vaccines or drugs are being administered in non-healthcare related facilities (e.g., outside of clinics or hospitals) and given to large numbers of individuals over a short period of time by a non- professional. Brief Description of the Drawings FIG. 1 is a perspective view of a delivery assembly consistent with the present disclosure and including a safety cover coupled thereto. FIG. 2 is a perspective view of the delivery assembly of FIG. 1 showing the safety cover removed to expose the administration member (i.e., needle). CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 FIG. 3 is an exploded perspective view of the delivery assembly of the present disclosure. FIG. 4A and 4B are perspective views illustrating attachment of a BFS vial to the delivery assembly of the present disclosure. FIG. 5 is a perspective view, partly in section, illustrating the BFS vial attached to the delivery assembly and showing engagement between the connection fittings of the BFS vial and the hub member of the delivery assembly of the present disclosure. FIG. 6A is an exploded, perspective sectional view of the delivery assembly. FIG. 6B is a perspective sectional view of the delivery assembly illustrating the components assembled to one another and forming a continuous fluid pathway there between. FIG. 6C is another perspective sectional view of the delivery assembly illustrating the components assembled to one another. FIG. 7A is an enlarged, perspective view, partly in section, illustrating the locking engagement between the connection fittings of the BFS vial and the hub member of the delivery assembly in greater detail. FIGS. 7B and 7C are enlarged, perspective views, partly in section, illustrating engagement between the distal end and outlet of the BFS vial with the one-way valve of the delivery assembly when the BFS vial is securely coupled to the delivery assembly. FIG. 8 shows perspective views of delivery assemblies consistent with the present disclosure and including different sized needles for different methods of delivery (e.g., intramuscular, subcutaneous, intravenous, and intradermal injection). FIG. 9 is a perspective view of a pack of BFS vials connected to a single manifold and having a breakaway detachment design. FIG. 10 is an enlarged perspective view of the breakaway detachment design of a BFS vial. FIG. 11 is a flow diagram illustrating the use of the delivery system of the present disclosure. Detailed Description The present invention provides a delivery system that overcomes the drawbacks of current delivery devices and methods. In particular, the delivery system of the present invention includes a delivery assembly configured to be coupled to a source containing a fluid agent (e.g., 6 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 vaccine, drug, medicament, etc.) and further facilitate delivery of a single dose of the fluid agent from the source to a patient. The delivery assembly is configured to be filled on-site and in the field with a single dose of a fluid agent, while remaining sterile and preventing the potential for contamination during the filling process. The delivery assembly is further capable of delivering the fluid agent in a controlled manner and without requiring specialized skill in administering delivery of such agent. The delivery assembly of the present invention is configured to be coupled to a source containing the fluid agent, including, but not limited to, a blow-fill-seal (BFS) vial. The delivery assembly includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another. The components of the delivery assembly include a hub member configured to be securely coupled to the BFS vial, a one- way valve member positioned within the hub member and configured to limit fluid flow to an antegrade direction, and an insert positioned within the hub member and configured to receive and retain an administration member for receiving the fluid agent from the BFS vial and administering the fluid agent into a patient. The administration member may include, for example, a needle (for subcutaneous, intramuscular, intradermal, or intravenous injection of the fluid agent) or a nozzle (e.g., spray nozzle to facilitate dispersion of the fluid agent into a spray or a droplet nozzle for formation of droplets). The modular construction of the delivery assembly allows for rapid manufacturing reconfigurations of one or more components with minimal costs to create new delivery assembly configurations that meet specific needs (i.e., different modes of delivery depending on agent to be delivered, such as subcutaneous, intramuscular, intradermal, intravenous injection, spray, or droplet delivery). For example, the hub member and the one-way valve may remain the same construction (dimensions and material), while the insert may be changed to account for different needle sizes and/or nozzle types, depending on the type of delivery and/or type of fluid agent to be delivered. The delivery assembly is configured to allow delivery of the agent to the patient in a relatively simple manner, without requiring specialized training for administering the agent. In particular, the delivery assembly is designed such that a person administering the fluid agent (e.g., administrator), which could also include self-administration, need only position the device upon the administration site (e.g., shoulder, arm, chest, nose, ear, eye, etc.), and then fully 7 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 compress the BFS vial body containing the dose of fluid agent, thereby delivering the correct predefined dosage to the patient. The delivery assembly itself is not prefilled. As such, the delivery assembly of the present invention does not require the maintenance of a certain temperature (e.g., 2 to 8 degrees Celsius) during shipment or storage, thus cutting down on the overall costs. Rather than maintaining the delivery assembly at a constant temperature, as is the case with current devices, only the source containing the fluid agent (e.g., single dose supply provided in a BFS vial) need by maintained at a constant temperature. Accordingly, a plurality of empty delivery assemblies may be shipped and stored, at a reduced cost, and then filled directly on-site and on an as-needed basis, such that only the single-dose BFS vials need be stored and maintained. Additionally, because the delivery device is not prefilled, it may be sterilized at any point prior to being filled with the fluid agent, which further improves the bulk shipping and storage of such devices. FIG. 1 is a perspective view of a delivery assembly 10 consistent with the present disclosure and including a safety cover 12 coupled thereto. FIG. 2 is a perspective view of the delivery assembly 10 showing the safety cover 12 removed. FIG. 3 is an exploded perspective view of the delivery assembly 10. As shown, the delivery assembly 10 includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another. The components of the delivery assembly 10 include a hub member 14 configured to be coupled to a source containing the fluid agent, including, but not limited to, a blow-fill-seal (BFS) vial, a one-way valve member 16 positioned within the hub member and configured to limit fluid flow to an antegrade direction, and an insert 18 positioned within the hub member and configured to receive and retain an administration member 20 for receiving the fluid agent from the BFS vial and administering the fluid agent into a patient. In some embodiments, the administration member 20 may include a needle for at least one of subcutaneous, intramuscular, intradermal, and intravenous injection of the fluid agent into the patient. For ease of explanation and description, the figures and the following description generally refer to the administration member as a needle. However, it should be noted that, in other embodiments, the administration member 20 may include a nozzle configured to control administration of the fluid agent to the patient. The nozzle may include a spray nozzle, for example, configured to facilitate dispersion of the fluid agent into a spray. Accordingly, a delivery assembly 10 fitted with a spray nozzle may be particularly useful in the administration 8 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 of a fluid agent into the nasal passage, for example, or other parts of the body that benefit from a spray application (e.g., ear canal, other orifices). In other embodiments, the nozzle may be configured to facilitate formation of droplets of the fluid agent. Thus, a delivery assembly 10 including a droplet nozzle may be useful in the administration of a fluid agent by way of droplets, such as administration to the eyes, topical administration, and the like. As generally understood, the fluid agent may include any type of agent to be injected into a patient (e.g., mammal, either human or non-human) and capable of producing an effect. Accordingly, the agent may include, but is not limited to, a vaccine, a drug, a therapeutic agent, a medicament, or the like. Referring to FIG. 3, the hub member 14 may include a body 22 having a proximal end 24 defining an inlet port and a distal end 26 defining an outlet port and a channel extending entirely from the proximal end 24 to the distal end 26, thereby providing a fluid pathway between inlet and outlet ports. The hub member 14 further includes includes a specialty, non- standard (non- Luer-type) connection fitting 28 configured to be coupled with a corresponding specialty, non- standard connection fitting of the BFS vial 100 (shown in FIGS. 4A and 5). For example, a portion of the hub member body 22 adjacent the proximal end 24 may include recesses, depressions, or complete apertures of a particular shape or geometry which are shaped and/or sized to receive correspondingly shaped and/or sized protrusions, projections, or the like on the BFS vial, as will be described in greater detail herein. In the embodiment shown in the figures, the hub member body 22 may include two opposing apertures 30a, 30b on either side of the hub member and adjacent to the proximal end 24, the apertures 30a, 30b being shaped and/or sized to receive and retain corresponding protrusions defined on the neck portion of a BFS vial, as will be described in greater detail herein. The hub member 14 further includes one or more window or port portions 28 formed on the body 22 and configured to provide a means for receiving and retaining a portion of the one-way valve 16 within. For example, the one-way valve 16 is generally positioned within the channel of the hub member 14 and is formed from a polymer material, such rubber, synthetic rubber, latex, or other elastomeric polymer material. The one-way valve 16 may be press-fit into the channel within the hub member 14, such that portions of the one-way valve 16 may extend through the window portions 28 and fill in any gaps so as to provide at least a watertight seal. The exposed one or more portions of the one-way valve 16 extending to the outer surface of the hub member 14 9 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 through the window portions 28 generally provide a friction fit for the interior surface of the safety cover 12 when the cover 12 is placed over the delivery assembly 10. In other words, the exposed polymer material of the one-way valve 16 generally provides sufficient friction with the cover 12 so as to keep the cover retained on to the delivery assembly. The one- way valve 16 includes a proximal end 32 and a distal end 34 and a channel extending therethrough and in coaxial alignment with the channel of the hub member 14. The one-way valve 16 further includes a valve flap provided within the channel and configured to limit fluid flow to an antegrade direction from the hub member 14 towards the administration member 20, thereby ensuring that fluid flows in a single direction when the fluid agent is delivered from a BFS vial. The proximal end 32 of the one-way valve is generally positioned closer to the proximal end 24 of the hub member and the distal end 34 of the one-way valve 16 is generally positioned closer to the distal end 26 of the hub member 14. The insert 18 is also positioned within the channel of the hub member 14 adjacent to the distal end 26 of the hub member 14. The insert 18 includes a proximal end 38 and an opposing distal end 40 and a channel extending entirely through the insert from the proximal end to the distal end. The channel of the insert 18 is in coaxial alignment with the channel of the hub member 14, such that a fluid pathway extends entirely from the proximal end 24 of the hub member 14, through the channels of the hub member 14, the one-way valve 16, and the insert 18 towards the distal end 40 of the insert 18. The proximal end 38 of the insert 14 is configured to be fitted within the channel of the one-way valve 16 adjacent to the distal end 34 of the one way valve 16. The administration member 20 (e.g., needle 20) is further received and retained within the channel at the distal end 40 of the insert 18, such that, upon delivery of the fluid agent from the BFS vial and through the fluid pathway of the delivery assembly 10, the fluid agent will flow out of the needle 20, thereby allowing for delivery of the fluid agent to the patient. As shown in FIGS. 1 and 2, the delivery assembly 10 further includes a safety cover 12 for covering the needle 20 to prevent contamination and further reduce the risk of needlestick injuries, and thus reduce the potential for spreading blood-borne diseases. The delivery assembly may generally be packaged and delivered in a fully assembled state, including the safety cover provided over the needle. Accordingly, a user does not have to deal with an exposed needle when first attaching a BFS vial to the delivery assembly. Rather, the user need only remove the safety cover once the BFS vial has been securely attached to the delivery CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 assembly to thereby expose the needle for fluid agent delivery. The user may then replace the cover once delivery is complete. The hub member 14, one-way valve 16, insert 18, and cover 12, are composed of a medical grade material. In some embodiments, the hub member 14, insert 18, and/or cover 12, may be composed of a thermoplastic polymer, including, but not limited to, polypropylene, polyethylene, polybenzimidazole, acrylonitrile butadiene styrene (ABS) polystyrene, polyvinyl chloride, PVC, or the like. FIG. 4A and 4B are perspective views illustrating attachment of a BFS vial 100 to the delivery assembly 10. As shown, the BFS vial may generally include a flexible body 102 having an interior volume sufficient to contain at least one dose of the fluid agent within. The BFS vial 100 further includes a neck extending from the body and terminating at a distal end 104 defining an outlet for dispensing the fluid agent upon squeezing of the vial body. The vial 100 is formed by blow-fill-seal technology. Blow-fill-seal (BFS) technology is a manufacturing technique used to produce liquid-filled containers. The vial 100 may be formed by BFS technology, in that the body 102, neck, and distal end 104 are formed, filled within a fluid agent, and sealed in a continuous process without human intervention, in a sterile enclosed area inside a machine. Accordingly, this process can be used to aseptically manufacture sterile pharmaceutical liquid dosage forms. Blow-fill-seal technology may be particularly attractive in the current market, as it reduces personnel intervention making it a more robust method for the aseptic preparation of sterile pharmaceuticals. As previously described, the hub member body 22 generally includes a specialty, non- standard connection fitting (apertures 30a, 30b) configured to be coupled with a corresponding specialty, non-standard connection fitting of the BFS vial 100. For example, the vial 100 may include two protrusions 106a, 106b defined on opposing sides of the neck adjacent to the distal end 104 and having a general shape corresponding to the apertures 30a, 30b on the hub member 14. Upon a user inserting the distal end 104 of the vial 100 into the proximal end 24 of the hub member 14, the protrusions 106a, 106b may be shaped so as to slide into engagement with the corresponding apertures 30a, 30b, respectively, as illustrated in FIG. 4B and indicated by arrows 48. FIG. 5 is a perspective view, partly in section, illustrating the BFS vial 100 attached to the delivery assembly 10 and showing engagement between the connection fittings of the BFS vial 100 and the hub member 14 of the delivery assembly 10. As shown, the protrusions 106a, 106b 11 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 on the neck of the vial 100 are in engagement with the corresponding apertures 30a, 30b of the hub member 14. The protrusions 106a, 106b are further shaped to prevent withdrawal of the BFS vial 100 from the hub member 14, thereby effectively locking themselves within the apertures 30a, 30b and effectively locking the BFS vial 100 into engagement with the delivery assembly 10. By securing the vial to the hub member, a user need only apply force to (i.e. squeeze) the vial body, as indicated by arrows 49, to cause the fluid agent to flow within the fluid pathway 50, the fluid agent traveling from the vial 100, through the delivery assembly 10 including through the needle 20, and into the patient. The specialty, non-standard connection fitting between the hub member and the BFS vial allows for only approved sources (e.g., single-dose BFS vials) with a corresponding agent to be used with the delivery assembly of the present disclosure, thereby adding one more layer of security. For example, the method of delivery is generally dependent on the type of fluid agent to be delivered. For example, some medicaments are best delivered intravenously while some vaccines are best delivered intradermally, and yet still, some fluid agents are administered via droplets or spray. Accordingly, the deliver assembly may configured for delivery of a specific fluid agent and thus the connection fitting on the hub member may be designed so as to only accept and engage a corresponding connection fitting of a BFS vial containing that specific fluid agent. Accordingly, the specialty connection fitting design of the present disclosure ensures that only the matching BFS vial (which contains the correct fluid agent for that specific delivery assembly) is able to be connected to the delivery assembly, thereby ensuring safety and reducing risk. FIG. 6A is an exploded, perspective sectional view of the delivery assembly 10. FIG. 6B is a perspective sectional view of the delivery assembly 10 illustrating the components assembled to one another and forming a continuous fluid pathway there between and FIG. 6C is another perspective sectional view of the delivery assembly 10 illustrating the components assembled to one another. As shown the hub member 14 includes an inlet port 25 at the proximal end 24 and an outlet port 58 at the distal end 26 and a channel extending therethrough. The hub member 14 further includes a flanged section 52 including a proximal end 54 and a distal end 56 to which the one-way valve 16 and insert 18 are coupled. In particular, the proximal end 32 of the one-way valve 16 is generally positioned on one side of the flanged section 52 (i.e., on the proximal end 54) and the distal end 34 of the one-way valve 16 generally 12 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 protrudes through a central bore in the flanged section 52 and is positioned on the other side of the flanged section 52 (i.e., on the distal end 56). The proximal end 38 of the insert 18 is received within the channel of the one-way valve 16 and extends into the distal end 34 of the one-way valve 16 and generally abuts the valve flap 60. The needle 20 has a hollow body 42 including a generally blunt proximal end 44 and a piercing distal tip 46. The proximal end 44 of the needle 20 is positioned within the channel 62 of the insert 18, wherein the channel 62 may have a stop or end portion (e.g., interior flange or tapered to a decreasing diameter) which prevents the proximal end 44 of the needle 20 from traveling too far down the channel 62. Once fully assembled, the fluid pathway 50 extends entirely through the delivery assembly 14, from the inlet port 25 of the hub member 14 to the distal tip 46 of the needle 20, and passing through each of the components (i.e., through the hub member 14, the one-way valve 16, and the insert 18). FIG. 7A is an enlarged, perspective view, partly in section, illustrating the locking engagement between the connection fittings of the BFS vial 100 and the hub member 14 of the delivery assembly 10 in greater detail. As previously described, the hub member body 22 generally includes a specialty, non-standard connection fitting (apertures 30a, 30b) configured to be coupled with a corresponding specialty, non-standard connection fitting of the BFS vial 100. For example, the vial 100 may include two protrusions 106a, 106b defined on opposing sides of the neck adjacent to the distal end 104 and having a general shape corresponding to the apertures 30a, 30b on the hub member 14. Upon a user inserting the distal end 104 of the vial 100 into the proximal end 24 of the hub member 14, the protrusions 106a, 106b may be shaped so as to slide into engagement with the corresponding apertures 30a, 30b, respectively, as illustrated in FIG. 4B and indicated by arrows 48. As shown, the protrusions 106a, 106b on the neck of the vial 100 are in engagement with the corresponding apertures 30a, 30b of the hub member 14. The protrusions 106a, 106b are further shaped to prevent withdrawal of the BFS vial 100 from the hub member 14, thereby effectively locking themselves within the apertures 30a, 30b and effectively locking the BFS vial 100 into engagement with the delivery assembly 10. FIGS. 7B and 7C are enlarged, perspective views, partly in section, illustrating engagement between the distal end 104 and outlet of the BFS vial 100 with the one-way valve 60 of the delivery assembly 10 when the BFS vial 100 is securely coupled to the delivery assembly 100. By securing the vial 100 to the hub member 14, the outlet of the distal end 104 of the vial 13 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 100 is in direct alignment with the valve flap 60 of the one-way valve 16, as indicated by arrow 108. Accordingly, the outlet of the vial 100 is in direct alignment with the fluid pathway 50. It should be noted that, due to some minor variations that commonly occur during the manufacturing process, BFS vial dimensions may be imprecise. For example, the distal end 104 of any given BFS vial 100 may have different dimensions when compared to one another (on a microscale). In order to compensate for such variation, connection fittings between the BFS vial 100 and the hub member 14 further ensure that the distal end 104 of the vial 100 is positioned against and into engagement with the proximal end 32 of the one-way valve 16. Due to the polymer material of the one-way valve 16, a seal may be created between the distal end 104 of the vial 100 and the proximal end 32 of the one-way valve 16, as indicated by arrows 64 in FIG. 7C, to thereby account for any imprecise manufacturing of the BFS vial 100. FIG. 8 shows perspective views of delivery assemblies consistent with the present disclosure and including different sized needles for different methods of delivery (e.g., intramuscular, subcutaneous, intravenous, and intradermal injection). For example, the needles 20a, 20b, 20c, and 20d may have length in the range of 1.5 mm to 25 mm. However, it should be noted that the needle length may be in the range of 0.5 mm to 50 mm. Accordingly, the modular construction of the delivery assembly allows for rapid manufacturing reconfigurations of one or more components with minimal costs to create new delivery assembly configurations that meet specific needs (i.e., different modes of delivery depending on agent to be delivered, such as subcutaneous, intramuscular, intradermal, intravenous injection, spray, or droplet delivery). For example, the hub member and the one-way valve may remain the same construction (dimensions and material), while the insert may be changed to account for different needle sizes and/or nozzle types, depending on the type of delivery and/or type of fluid agent to be delivered. FIG. 9 is a perspective view of a pack 200 of BFS vials 100(1)-100(5) connected to a single manifold 202 and having a breakaway detachment design. FIG. 10 is an enlarged perspective view of the breakaway detachment design of a BFS vial 100. As shown, each BFS vial contains a single dose of fluid agent and, when a user is ready, a single vial may be removed via a tear away type connection with the manifold 202, indicated at arrow 204. In particular, the distal end 104, and thus the outlet, of each vial 100 is coupled to the manifold 202. By simply pulling the desired vial 100 away from the common manifold 202, a user is able to separate the single vial from the remaining vials and use only the single dose that is required, rather than 14 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 using a larger source of fluid agent (multiple dose syringe or vial), thereby completely preventing the risk of contaminating a single source of fluid agent. The pack 200 may be beneficial in that indicia imprinting may be provided on the manifold 202 itself and/or each individual vial 100(1)-100(5). Exemplary indicia may include, but is not limited to, lot number, expiration date, medication information, security stamp (color changing temperature sensor to provide indication of whether vials have or have not been maintained at required temperature), as well as the dose line provided on each vial. FIG. 11 is a flow diagram illustrating the use of the delivery system of the present disclosure. As shown, the delivery system may be delivered with a pack of BFS vials and a corresponding number of fully assembled delivery assemblies with safety covers. A user simply tears away one of the vials when ready to deliver the single dose of fluid agent and then attaches the vial to a delivery assembly. The user then removes the safety cover, thereby exposing the needle and then administers the fluid agent (either self-administration or administration to another person). Once finished, the safety cover can be placed back on to the delivery assembly and the contents can be discarded in the appropriate biohazard waste receptacle. The delivery assembly is configured to allow delivery of the agent to the patient in a relatively simple manner, without requiring specialized training for administering the agent. In particular, the delivery assembly is designed such that a person administering the fluid agent (e.g., administrator), which could also include self-administration, need only position the device upon the administration site (e.g., shoulder, arm, chest, nose, ear, eye, etc.), and then fully compress the BFS vial body containing the dose of fluid agent, thereby delivering the correct predefined dosage to the patient. The delivery assembly is further configured such that, in the event that a needle is required (i.e., because the delivery method is an injection), needle penetration is limited to the correct length and orientation within the administration site. For example, in some embodiments, the needle is positioned substantially perpendicular relative to a plane along which the distal end of the insert lies, such that the needle is configured to be inserted into a patient's skin at a substantially perpendicular angle and the distal end of the insert is configured to contact the patient's skin indicating adequate depth of penetrating for injection of the fluid agent. Accordingly, the delivery assembly of the present invention does not require a trained, skilled healthcare profession for administration of vaccines or drugs. As such, the delivery CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 assembly may be particularly useful in situations in which vaccines or drugs are being administered in non-healthcare related facilities (e.g., outside of clinics or hospitals) and given to large numbers of individuals over a short period of time by a non- professional. While several embodiments of the present disclosure have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the functions and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the present disclosure. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the teachings of the present disclosure is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, the disclosure may be practiced otherwise than as specifically described and claimed. The present disclosure is directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the scope of the present disclosure. All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms. The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one." The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, 16 CA 03021989 2018-10-23 WO 2017/187262 PCT/IB2017/000549 whether related or unrelated to those elements specifically identified, unless clearly indicated to the contrary. Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described (or portions thereof), and it is recognized that various modifications are possible within the scope of the claims. Accordingly, the claims are intended to cover all such equivalents. Incorporation by Reference References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Equivalents Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof. 17